# Heart Tumor Market > Heart Tumor Market Research Report Information by Tumor Type (Primary Tumors and Secondary Tumors), by Diagnosis & Treatment (Diagnosis & Treatment), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.04% - **2024:** $ 1.02 Billion - **2025:** $ 1.08 Billion - **2035:** $ 1.94 Billion - **Key Players:** Bristol-Myers Squibb (US), Novartis (CH), Roche (CH), Pfizer (US), Merck & Co. (US), AstraZeneca (GB), Eli Lilly and Company (US), Bayer (DE), Amgen (US) **Report ID:** MRFR/HC/3629-CR · **Pages:** 137 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** March 28, 2026 **URL:** https://www.marketresearchfuture.com/reports/heart-tumor-market-5065 --- ## Market Summary ## **Heart Tumor Market Overview:** Heart Tumor Market Size was valued at USD 0.95 Billion in 2023. The Global Heart Tumor industry is projected to grow from USD 1.02 Billion in 2024 to USD 1.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.04% during the forecast period (2024 - 2032). An abnormal growth of heart tissue is referred to as a cardiac tumor, which can be either cancerous (malignant) or non-cancerous. Cardiac Tumor can also be categorized as primary (coming from the heart itself) or secondary. Primary cardiac tumor is extremely uncommon, affecting just around 1 in 3000 people. The majority of initial heart tumor—75%—are benign. Secondary cardiac tumor most frequently develops in people with lung cancer, breast cancer, melanoma, renal cell carcinoma, or lymphoma and are 20–30 times more likely than primary cardiac tumor. The market is driven by factors like the growing prevalence of cardiac tumors, increasing number of cancer research and funding, and the rising number of strategic initiatives. Nevertheless, increasing initiatives by public and private organizations to drive awareness regarding heart tumor is anticipated to create lucrative opportunities for the players operating in the heart tumor market. However, lack of awareness among people, and lack of skilled radiologists could hamper the growth of the heart tumor market. **COVID-19 Analysis** The COVID-19 pandemic had negatively impacted the heart tumor market in the initial phase of the pandemic, causing a reduction in productivity, shutdown/reduced activity in manufacturing plants, and disruption in the supply chain. However, the COVID-19 pandemic has moderately disrupted the production and revenue of many companies. Most key players have their manufacturing units in different regions which were highly affected by this pandemic due to restriction laid down by the authorities to curb virus transmission. Key companies such as Koninklijke Philips N.V. (Netherlands), Siemens AG (Germany), Hitachi, Ltd. (Japan), GE Healthcare (US) and others are highly dependent on several regional markets for revenue generation, but the pandemic and slowdown globally had negatively affected the company’s growth in these regions in 2020. For instance, the shortage of Iodinated Contrast Media (ICM) due to a General Electric manufacturing shutdown in Shanghai, China owing to COVID-19 lockdown in April 2022, has caused significant effects on radiology practices globally. **Heart Tumor Market Dynamics** **Market Drivers** **Market Restraints** **Market Opportunities** **Value Chain Analysis** The value chain analysis for the heart tumor market comprises four major components that start with the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and ends with post-sales monitoring. In the research and product development stage, new techniques and research are undertaken to develop new products, and to make the existing products better and unique. In manufacturing stage, the product strategies are ready, and the manufacturing process of the product starts. In distribution & sales, the company's marketing and sales strategies play a crucial role in understanding the characteristics of the industry in which one is competing. Many players sponsor seminars, knowledge sessions, and other activities, including checking for potential interactions and providing advice, each of which is expected to guarantee the end user gets the awareness, full advantage, and value from the products accordingly. Furthermore, in the post-marketing monitoring stage, it begins with a periodic safety update report of the drug or device to be submitted to the FDA after the drug or device comes into the market. **Segment Overview** **Tumor Type** Primary Heart Cardiac (PCT) is a deadly and uncommon condition. Primary tumors are classified into malignant and benign. For instance, according to a SpringerLink article from October 2020, 10% are malignant tumors that are pathologically labelled as sarcomas, and about 90% are benign tumors. Moreover, the major benign tumors that have high chances of becoming malignant are myxomas, rhabdomyoma, and others, including fibromas, lipomas, hemangiomas, papillary fibroelastomas, cystic tumors of the atrioventricular node, and paragangliomas. [Soft tissue sarcomas](../../../reports/soft-tissue-sarcoma-market-5304) are the common PCTs. The common secondary cardiac tumor is epicardial compared to myocardial and endocardial, and only 10% are symptomatic secondary tumors. For instance, in June 2020, a ScienceDirect article on cardiac tumors reported that SCTs are 20 to 40 times common and frequent than Primary Cardiac Tumors (PCTs). At autopsy, approximately 12% of patients are diagnosed with SCTs, with the majority remaining clinically silent. **By Diagnosis & Treatment** The heart tumor can be diagnosed by CT scans, Magnetic Resonance Imaging (MRI) scans, nuclear imaging, echocardiography, and others. The cardiac CT scan is used to identify narrowed or blocked arteries. Moreover, cardiac [MRI](../../../reports/magnetic-resonance-imaging-systems-market-6194) provides multiplanar information related to the cardiac masses, including surrounding structures. It is also beneficial due to the appropriate identification of benign and malignant tumors as well as in providing psuedomass information. In addition, other diagnosis methods includes for heart tumor is Electrocardiogram (ECG), electrophysiology tests and cardiac biopsy. The treatment segment includes surgery, chemotherapy, radiotherapy, and others. Surgical procedures include surgical excision, transplantation, and [catheterization](../../../reports/cardiac-catheterization-market-972). Additionally, Surgery removes the growth of cancerous tumors or cancerous tumors. For instance, according to the Journal of Cardiothoracic Surgery published in April 2019, it is effective, durable, and safe for primary benign cardiac tumors. A study conducted in the Journal of Cardiothoracic Surgery from 2008 to 2018 showed that 19 men and 31 women were enrolled with left atrium (80.0%), right atrium (16.0%), right ventricle (2.0%), and left ventricle (2.0%) from age 55 to 17.5 years. **Regional Analysis** GLOBAL HEART TUMOR MARKET SHARE (%), BY Region, 2021Source: MRFR analysis The North America held the largest market share of 40.72% based on region and is anticipated to dominate the overall heart tumor market during the forecast period. **North America** The North America comprising the US and Canada— North America held the largest market share in 2021. This is due to factors such as the major use of cardiac biopsies and high prevalence of PCTs in the region. According to a research article published in the International Journal of Surgery (IJS) by Mohamed Rahouma et al, in March 2020, a meta-analysis on cardiac tumors and the utilization of heart transplantation was performed. Primary Malignant Cardiac Tumors (PMCTs) are a minority of Primary Cardiac Tumors (PCTs) and are more prevalent in North America and Europe than in other regions, which is supplementing demand for the heart tumor market **north america HEART TUMOR MARKET SHARE (%), BY country, 2021**Source: MRFR analysis **Asia-pacific** Asia-Pacific is anticipated to register the highest CAGR of 8.06% over the forecast period. This is due to factors like presence off several key companies and they are actively investing and expanding through acquisitions, mergers, expansion, and product launches in the region. According to an article published in June 2018 by the International Society of [Ultrasound](../../../reports/ultrasound-devices-market-2789) in Obstetrics and Gynecology (ISUOG), cardiac rhabdomyoma tumor is the most common cardiac tumor in the fetus in Japan. **Competitive Landscape** The global heart tumor market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency. Market Research Future’s analysis revealed that market players have adopted different strategies and innovative research and development techniques to expand their business and secure their position in the global preclinical heart tumor market. In recent years, strategic movements by major players included approvals, which have been used as market penetration strategies and a means to reduce competition Moreover, the major players have adopted strategies such as acquisitions, expansion, and collaborations to augment their position in the market. For instance, in April, 2022 Shimadzu Corporation (Japan) launched the Trinias Angiography system to improve medical device visibility. It contains extra customization capabilities that allow for the establishment of a basic, user-friendly workspace that allows for successful operation in a medical setting **List of companies with HQ** **Recent Developments** **Report Overview** The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market. **Study Objectives** **Market Segmentation:** **Global Heart Tumor Market, Tumor Type** **Global Heart Tumor Market, By Diagnosis & Treatment** **Global Heart Tumor Market,****By Region** ## Market Drivers ### Rising Incidence of Heart Tumors The increasing incidence of heart tumors is a primary driver for the Heart Tumor Market. Recent data indicates that the prevalence of cardiac tumors has been on the rise, with estimates suggesting that approximately 0.02% to 0.3% of all cardiac tumors are malignant. This growing incidence necessitates enhanced diagnostic and therapeutic options, thereby propelling market growth. As healthcare systems adapt to this trend, investments in research and development are likely to increase, fostering innovation in treatment modalities. Furthermore, the aging population, which is more susceptible to various forms of cancer, contributes to the rising number of heart tumor cases. Consequently, the Heart Tumor Market is expected to expand as healthcare providers seek to address this pressing health concern. ### Rising Patient Awareness and Advocacy Rising patient awareness and advocacy are playing a pivotal role in shaping the Heart Tumor Market. As patients become more informed about heart tumors and their treatment options, there is a growing demand for comprehensive care and support services. Advocacy groups are actively promoting education and awareness campaigns, which are instrumental in encouraging early detection and timely intervention. This heightened awareness is likely to lead to increased screening and diagnostic testing, ultimately contributing to market growth. Additionally, as patients seek more personalized treatment options, healthcare providers are compelled to adapt their services to meet these expectations. The Heart Tumor Market is thus experiencing a shift towards patient-centered care, driven by the collective efforts of advocacy organizations and informed patients. ### Technological Advancements in Treatment Technological advancements in treatment methodologies are significantly influencing the Heart Tumor Market. Innovations such as minimally invasive surgical techniques, targeted therapies, and advanced imaging technologies are transforming the landscape of cardiac tumor management. For instance, the introduction of robotic-assisted surgeries has improved surgical outcomes and reduced recovery times for patients. Additionally, the development of novel pharmacological agents that target specific tumor markers is enhancing treatment efficacy. Market data suggests that the adoption of these technologies is likely to increase, as healthcare providers aim to improve patient outcomes and reduce healthcare costs. As a result, the Heart Tumor Market is poised for growth, driven by the continuous evolution of treatment options that cater to the unique needs of patients. ### Increased Research and Development Activities Increased research and development activities are propelling the Heart Tumor Market forward. The scientific community is actively engaged in exploring novel therapeutic approaches and understanding the underlying mechanisms of heart tumors. Recent studies have highlighted the importance of genetic profiling in tailoring treatment strategies, which is likely to enhance the effectiveness of interventions. Furthermore, collaborations between academic institutions and pharmaceutical companies are fostering innovation in [drug development](https://www.marketresearchfuture.com/reports/drug-development-market-66529). Market data indicates that R&D spending in oncology is expected to rise, reflecting a commitment to addressing the challenges posed by heart tumors. This surge in research efforts is anticipated to yield new treatment options and improve existing therapies, thereby driving growth in the Heart Tumor Market. ### Growing Investment in Healthcare Infrastructure The growing investment in healthcare infrastructure is a crucial driver for the Heart Tumor Market. Governments and private entities are increasingly allocating resources to enhance healthcare facilities, particularly in oncology and cardiology departments. This trend is evident in various regions, where new hospitals and specialized treatment centers are being established to cater to the rising demand for heart tumor management. According to recent reports, healthcare expenditure is projected to increase, with a focus on advanced diagnostic and therapeutic technologies. This influx of investment is likely to facilitate the development of comprehensive care pathways for patients with heart tumors, thereby expanding the Heart Tumor Market. Enhanced infrastructure not only improves access to care but also fosters collaboration among healthcare professionals, ultimately benefiting patient outcomes. ## Future Outlook The Heart Tumor Market is projected to grow at a 6.04% CAGR from 2025 to 2035, driven by advancements in diagnostic technologies, increasing prevalence, and enhanced treatment options. **New opportunities:** - Development of targeted therapies for specific heart tumor types. - Expansion of telemedicine platforms for remote patient monitoring. - Investment in AI-driven diagnostic tools for early detection. By 2035, the Heart Tumor Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and technological advancements. ## Segment Insights ### By Tumor Type: Primary Tumor (Largest) vs. Secondary Tumor (Fastest-Growing) In the Heart Tumor Market, the primary tumor segment holds a significant portion of the market share, reflecting its established presence and recognition among healthcare providers. Primary tumors, originating within the heart, account for the majority of cases, thereby shaping market dynamics and treatment approaches. In contrast, the secondary tumor segment has emerged as a rapidly growing area of concern, primarily due to the increasing incidence of metastatic diseases that affect the heart, leading to a notable shift in treatment priorities and market focus. Tumor Type: Primary (Dominant) vs. Secondary (Emerging) The primary tumor segment is characterized by tumors that develop as the initial site in the heart, such as myxomas and sarcomas. These tumors are often diagnosed earlier due to their distinct symptoms and the patient's direct interaction with healthcare systems. On the other hand, secondary tumors arise from cancers originating elsewhere in the body and metastasize to the heart. This segment is witnessing increased attention as advancements in oncology lead to better survival rates, thereby growing the need for targeted therapeutic approaches in treating these patients. As research continues to evolve, both segments attract unique treatment regimens designed to address their specific biological behaviors and distinct clinical challenges. ### By Diagnosis: MRI Scan (Largest) vs. CT Scan (Fastest-Growing) The 'Diagnosis' segment in the Heart Tumor Market is characterized by a diverse range of imaging technologies used for identification and assessment. Among these, MRI Scans hold the largest market share, owing to their superior imaging capabilities that provide detailed views of soft tissue structures, which are crucial for accurately diagnosing heart tumors. In contrast, CT Scans are emerging rapidly, capturing market interest due to advancements in technology that enhance their imaging precision and reduce radiation exposure, positioning them as the fastest-growing diagnostic tool in this segment. MRI Scan (Dominant) vs. CT Scan (Emerging) MRI Scans represent the dominant technology in the Heart Tumor diagnosis segment, largely because of their ability to capture multi-directional images without radiation exposure, making them ideal for soft tissue evaluation. Hospitals and specialized clinics prefer MRI for initial diagnostics and treatment planning due to its efficacy in detailing soft tissue lesions. On the other hand, CT Scans are considered an emerging diagnostic solution, driven by recent innovations that have improved image resolution and scan speed, coupled with lower operational costs. Their efficiency in quickly imaging large areas of the heart makes them a favorable option in emergency settings, further contributing to their rapid adoption and growth in the market. ### By Treatment: Surgery (Largest) vs. Chemotherapy (Fastest-Growing) In the Heart Tumor Market, the Treatment segment is primarily divided among Surgery, Chemotherapy, Radiotherapy, and Others. Currently, Surgery holds the largest market share, benefiting from its established role as a primary intervention for heart tumors. Meanwhile, Chemotherapy is recognized for its growing application, which is reflected in its rapid increase in utilization. Radiotherapy and Others contribute to the segment but on a comparatively smaller scale, often used in conjunction with the dominant treatments. Surgery (Dominant) vs. Chemotherapy (Emerging) Surgery is the dominant approach in the treatment of heart tumors, providing direct intervention and often leading to curative outcomes for patients. It includes various techniques such as resection and minimal invasive methods. In contrast, Chemotherapy is emerging rapidly as a supportive treatment, particularly for patients with inoperable tumors or as an adjuvant therapy post-surgery. This shift is driven by advances in pharmacology and [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), which enhance the effectiveness of chemotherapy regimens. As research progresses, the synergy between surgical methods and chemotherapy is expected to grow stronger, emphasizing the importance of integrated treatment approaches for heart tumors. ## Regional Market Share Analysis ### North America : Leading Innovation and Research North America is the largest market for heart tumor treatments, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a high prevalence of heart-related diseases. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, driving market growth. The increasing demand for personalized medicine and targeted therapies further fuels this expansion. The United States is the primary contributor to this market, with key players such as Bristol-Myers Squibb, Pfizer, and Merck & Co. leading the charge. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotech firms. Canada also plays a significant role, focusing on research collaborations and clinical trials, enhancing the overall market dynamics. ### Europe : Regulatory Support and Growth Europe is the second-largest market for heart tumor treatments, holding around 30% of the global market share. The region's growth is driven by increasing awareness of heart tumors, advancements in diagnostic technologies, and supportive regulatory frameworks from the European Medicines Agency (EMA). Countries like Germany and France are at the forefront, with a rising demand for innovative therapies and a focus on improving patient outcomes. Germany leads the market, supported by a robust healthcare system and significant investments in medical research. France and the UK also contribute substantially, with numerous clinical trials and collaborations among key players like Novartis and Roche. The competitive landscape is evolving, with a mix of established companies and startups focusing on novel treatment options, enhancing the region's market potential. ### Asia-Pacific : Rapidly Growing Healthcare Sector Asia-Pacific is an emerging powerhouse in the heart tumor market, accounting for approximately 20% of the global share. The region's growth is propelled by increasing healthcare expenditure, rising awareness of heart diseases, and a growing aging population. Countries like China and India are witnessing significant advancements in healthcare infrastructure, which are crucial for the adoption of innovative treatment options. Regulatory bodies are also becoming more supportive, facilitating faster approvals for new therapies. China is the largest market in the region, with a rapidly expanding pharmaceutical sector and a focus on research and development. India follows closely, with a growing number of clinical trials and collaborations among local and international players. The competitive landscape is marked by the presence of both global giants and local firms, creating a dynamic environment for innovation and growth. ### Middle East and Africa : Emerging Market with Challenges The Middle East and Africa represent a smaller segment of the heart tumor market, holding about 5% of the global share. However, the region is witnessing gradual growth driven by increasing healthcare investments, rising awareness of heart diseases, and improving access to advanced medical technologies. Countries like South Africa and the UAE are leading the way, focusing on enhancing healthcare infrastructure and regulatory frameworks to support new treatments. South Africa is the largest market in the region, with a growing number of healthcare facilities and initiatives aimed at improving patient care. The competitive landscape is characterized by a mix of local and international players, with a focus on addressing the unique healthcare challenges faced in the region. Collaborative efforts among governments and private sectors are essential for fostering innovation and expanding market access. ## Competitive Benchmarking The Heart Tumor Market is currently characterized by a dynamic competitive landscape, driven by advancements in treatment modalities and a growing emphasis on personalized medicine. Key players such as Bristol-Myers Squibb (US), Novartis (CH), and Roche (CH) are at the forefront, each adopting distinct strategies to enhance their market presence. Bristol-Myers Squibb (US) focuses on innovative immunotherapy solutions, while Novartis (CH) emphasizes its robust pipeline of targeted therapies. Roche (CH) leverages its strong diagnostic capabilities to complement its therapeutic offerings, thereby creating a comprehensive approach to heart tumor management. Collectively, these strategies not only enhance their competitive positioning but also contribute to a more integrated treatment paradigm in the market. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Heart Tumor Market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Pfizer (US) and Merck & Co. (US) is notable, as they engage in strategic collaborations and partnerships that further consolidate their market positions. In August 2025, Pfizer (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel heart tumor therapy. This collaboration is significant as it not only expands Pfizer's therapeutic portfolio but also enhances its research capabilities in the rapidly evolving field of oncology. Such partnerships are likely to accelerate the development of innovative treatments, positioning Pfizer as a key player in the market. In September 2025, Merck & Co. (US) launched a new clinical trial for its promising heart tumor immunotherapy. This initiative underscores Merck's commitment to advancing treatment options and reflects a broader trend towards personalized medicine. The trial's outcomes could potentially reshape treatment protocols and solidify Merck's standing in the competitive landscape. Additionally, in July 2025, Novartis (CH) received regulatory approval for a groundbreaking heart tumor therapy that utilizes advanced gene-editing technology. This approval not only marks a pivotal moment for Novartis but also highlights the increasing importance of innovative technologies in the treatment of heart tumors. The successful implementation of such therapies could redefine patient outcomes and set new standards in the market. As of October 2025, the Heart Tumor Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming increasingly vital, as they enable companies to pool resources and expertise, thereby enhancing their competitive edge. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition is likely to foster a more collaborative environment, ultimately benefiting patients through improved treatment options. ## Report Scope | MARKET SIZE 2024 | 1.02(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.082(USD Billion) | | MARKET SIZE 2035 | 1.944(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.04% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Bristol-Myers Squibb (US), Novartis (CH), Roche (CH), Pfizer (US), Merck & Co. (US), AstraZeneca (GB), Eli Lilly and Company (US), Bayer (DE), Amgen (US) | | Segments Covered | Tumor Type, Diagnosis & Treatment, Region | | Key Market Opportunities | Advancements in minimally invasive surgical techniques enhance treatment options in the Heart Tumor Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the heart tumor treatment landscape. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Heart Tumor Market as of 2024?** A: The Heart Tumor Market was valued at 1.02 USD Billion in 2024. **Q: What is the projected market valuation for the Heart Tumor Market in 2035?** A: The market is projected to reach 1.944 USD Billion by 2035. **Q: What is the expected CAGR for the Heart Tumor Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Heart Tumor Market during 2025 - 2035 is 6.04%. **Q: Which companies are the key players in the Heart Tumor Market?** A: Key players include Bristol-Myers Squibb, Novartis, Roche, Pfizer, Merck & Co., AstraZeneca, Eli Lilly and Company, Bayer, and Amgen. **Q: What are the primary and secondary tumor segment valuations in the Heart Tumor Market?** A: The primary tumor segment was valued at 0.612 USD Billion, while the secondary tumor segment was valued at 0.408 USD Billion. **Q: How do diagnostic methods contribute to the Heart Tumor Market?** A: Diagnostic methods such as CT scans and MRI scans contributed 0.25 USD Billion and 0.2 USD Billion, respectively, to the market. **Q: What treatment options are available in the Heart Tumor Market and their valuations?** A: Surgery, chemotherapy, and radiotherapy were valued at 0.4 USD Billion, 0.3 USD Billion, and 0.2 USD Billion, respectively. **Q: What is the valuation of the 'Others' segment in the diagnosis category?** A: The 'Others' segment in the diagnosis category was valued at 0.22 USD Billion. **Q: How does the Heart Tumor Market's growth compare to other oncology markets?** A: The Heart Tumor Market's growth appears robust, with a projected CAGR of 6.04%, indicating a strong upward trend. **Q: What factors might influence the growth of the Heart Tumor Market in the coming years?** A: Factors such as advancements in treatment options and increased awareness of heart tumors may influence market growth positively. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/heart-tumor-market-5065*